» Articles » PMID: 23246330

Serial Diffusion-weighted MRI in Patients with Hepatocellular Carcinoma: Prediction and Assessment of Response to Transarterial Chemoembolization. Preliminary Experience

Overview
Journal Eur J Radiol
Specialty Radiology
Date 2012 Dec 19
PMID 23246330
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess the role of apparent diffusion coefficient (ADC) measured with diffusion-weighted imaging (DWI) in predicting and assessing response of hepatocellular carcinoma (HCC) to transarterial chemoembolization (TACE).

Methods: Thirty-six patients with cirrhosis and untreated HCC who underwent TACE and MRI within 3 months before and after TACE were assessed. MRI included DWI and contrast-enhanced T1-weighted imaging. Two observers measured ADC of HCCs and liver parenchyma on pre- and post-TACE MRIs and measured degree of tumor necrosis on subtracted post-contrast images on post-TACE MRI. Pre-, post-TACE tumor ADC, and changes in tumor ADC (ΔADC) were compared between lesions stratified by degree of tumor necrosis (measured on post-TACE MRI).

Results: Forty seven HCCs were evaluated (mean size 4.4cm, range 1.0-14.1cm). HCCs with poor and incomplete response to TACE (<50% necrosis on post-TACE MRI) had significantly lower pre-treatment ADC and lower post TACE ADC compared to HCCs with good/complete response (≥50% necrosis): ADC pre-TACE 1.35±0.42 vs. 1.64±0.39×10(-3)mm(2)/s (p=0.042); post-TACE ADC 1.34±0.36 vs. 1.92±0.47 (p=0.0008). There was no difference in ΔADC values.

Conclusion: This preliminary data suggests that pre-TACE tumor ADC can be used to predict HCC response to TACE.

Citing Articles

Interstitial Brachytherapy of the Liver for Renal Cell Carcinoma: ADC Measurements Do Not Predict Overall Survival.

Thormann M, Heitmann F, Wrobel V, March C, Pech M, Surov A In Vivo. 2022; 36(6):2945-2951.

PMID: 36309358 PMC: 9677782. DOI: 10.21873/invivo.13037.


Diagnostic Accuracy of the Apparent Diffusion Coefficient for Microvascular Invasion in Hepatocellular Carcinoma: A Meta-analysis.

Deng Y, Li J, Xu H, Ren A, Wang Z, Yang D J Clin Transl Hepatol. 2022; 10(4):642-650.

PMID: 36062283 PMC: 9396311. DOI: 10.14218/JCTH.2021.00254.


Prediction of post transarterial chemoembolization MR images of hepatocellular carcinoma using spatio-temporal graph convolutional networks.

Svecic A, Mansour R, Tang A, Kadoury S PLoS One. 2021; 16(12):e0259692.

PMID: 34874934 PMC: 8651128. DOI: 10.1371/journal.pone.0259692.


Apparent Diffusion Coefficient Can Predict Therapy Response of Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization.

Drewes R, Heinze C, Pech M, Powerski M, Woidacki K, Wienke A Dig Dis. 2021; 40(5):596-606.

PMID: 34749359 PMC: 9501788. DOI: 10.1159/000520716.


Diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging after radiation therapy for bone metastases in patients with hepatocellular carcinoma.

Lee J, Yoo G, Yoon Y, Park H, Kim H Sci Rep. 2021; 11(1):10459.

PMID: 34001997 PMC: 8128906. DOI: 10.1038/s41598-021-90065-1.